An observational study in Brain Abscess, sponsored by Assistance Publique - Hôpitaux de Paris. Not yet recruiting. Open to participants aged 0 Years to 100 Years. Per ClinicalTrials.gov, last updated 2024-02-05.
Sponsored by Assistance Publique - Hôpitaux de Paris · Observational
Allotransplantation is the process of transferring organ(s), tissue(s) or cell(s) from a healthy donor to a recipient. The two main applications of allotransplantation are solid organ transplantation and allogeneic hematopoietic stem cell transplantation. For several reasons, including the need to use immunosuppressive drugs after transplantation, recipients of allografts carry a high risk of infectious complications.
Central nervous system infections are dreadful complications of transplantation, which can be divided into brain abscesses, meningitis, and encephalitis. In particular, brain abscesses pose major diagnostic and therapeutic challenges to transplant physicians, and are frequently fatal in transplant recipients. As compared with immunocompetent patients, transplant recipients and other immunocompromised patients have an increased risk of brain abscesses due to opportunistic pathogens, including fungi, parasites, bacteria, and mycobacteria.
Determining the epidemiology of brain abscesses is critical to guide transplant teams regarding the diagnosis and management of brain abscesses in transplant recipients.
Because the incidence of brain abscesses is low after transplantation, transplant teams often have limited clinical experience in the management of these infections. Similarly, most publications focusing on post-transplant brain abscesses are either case reports, small case series, or review articles.
We therefore aim to conduct a multicentre retrospective study on the epidemiology, the characteristics, and the outcome of brain abscesses in transplant recipients in the era of new diagnostic tools and progress in prophylaxis.
41 studies on the registry are indexed under Opportunistic Infections; 12 are open to participants now.
This study's planned enrollment of 200 is below the median of 504 across 20 observational studies indexed under Opportunistic Infections.
Browse Opportunistic Infections studies →Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,596 studies on the registry; 1,037 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients with brain abscesses after transplantation
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Other: Retrospective follow-up
Data collection
Description of the current epidemiology of brain abscesses in transplant recipients
Clinical and microbiological characteristics
Time frame: 1 year after brain abscess diagnosis
Comparison of the clinical and microbiological characteristics of brain abscesses between solid organ transplant recipients and allogeneic hematopoietic stem cell transplant recipients
Time frame: 1 year after brain abscess diagnosis
Compare the clinical and microbiological characteristics of brain abscesses occurring early after transplantation (<M6) with those of brain abscesses occurring later after transplant (> M6)
Time frame: 1 year after brain abscess diagnosis
Identification of clinical predictors associated with fungal brain abscesses versus brain abscesses due to non-fungal organisms
Time frame: 1 year after brain abscess diagnosis
Description of the current management of post-transplant brain abscesses in transplant recipients
in terms of antimicrobial therapy, immunomodulation, and neurosurgical management
Time frame: 1 year after brain abscess diagnosis
Assessment of the outcome of transplant recipients with brain abscesses
i.e. one-year all cause mortality
Time frame: 1 year after brain abscess diagnosis
Identification of factors associated with patient survival in transplant recipients with brain abscesses
Time frame: 1 year after brain abscess diagnosis
No study locations are listed for this record.
Plan to share: Undecided
No publications or documents are linked to this record.
Start is estimated for Feb 2024; primary completion for Feb 2025, 12 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Assistance Publique - Hôpitaux de Paris →